Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | KDMN | Stock Option (right to buy) | Disposed to Issuer | -$269K | -50K | -100% | $5.38 | 0 | Nov 9, 2021 | Common Stock, par value $0.001 | 50K | $4.12 | Direct | F1, F2 |
transaction | KDMN | Stock Option (right to buy) | Disposed to Issuer | -$308K | -50K | -100% | $6.15 | 0 | Nov 9, 2021 | Common Stock, par value $0.001 | 50K | $3.35 | Direct | F1, F2 |
transaction | KDMN | Stock Option (right to buy) | Disposed to Issuer | -$721K | -100K | -100% | $7.21 | 0 | Nov 9, 2021 | Common Stock, par value $0.001 | 100K | $2.29 | Direct | F1, F2 |
transaction | KDMN | Stock Option (right to buy) | Disposed to Issuer | -$516K | -102K | -100% | $5.06 | 0 | Nov 9, 2021 | Common Stock, par value $0.001 | 102K | $4.44 | Direct | F1, F2 |
transaction | KDMN | Stock Option (right to buy) | Disposed to Issuer | -$689K | -116K | -100% | $5.92 | 0 | Nov 9, 2021 | Common Stock, par value $0.001 | 116K | $3.58 | Direct | F1, F2 |
Tasos Konidaris is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
F2 | Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. |